These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26514420)

  • 1. Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.
    Cross AS; Greenberg N; Billington M; Zhang L; DeFilippi C; May RC; Bajwa KK
    Vaccine; 2015 Nov; 33(48):6719-26. PubMed ID: 26514420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.
    Cross AS; Opal SM; Palardy JE; Drabick JJ; Warren HS; Huber C; Cook P; Bhattacharjee AK
    Vaccine; 2003 Nov; 21(31):4576-87. PubMed ID: 14575770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum.
    Cross AS; Karreman HJ; Zhang L; Rosenberg Z; Opal SM; Lees A
    Vaccine; 2014 Oct; 32(46):6107-14. PubMed ID: 25242628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an anti-endotoxin vaccine for sepsis.
    Cross AS
    Subcell Biochem; 2010; 53():285-302. PubMed ID: 20593272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
    Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
    Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors.
    Chen WH; Basu S; Bhattacharjee AK; Cross AS
    Innate Immun; 2010 Oct; 16(5):322-32. PubMed ID: 19822632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gram-negative bacterial pneumonia.
    Chen WH; Kang TJ; Bhattacharjee AK; Cross AS
    Innate Immun; 2008 Oct; 14(5):269-78. PubMed ID: 18809651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC
    Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.
    Fransen F; Boog CJ; van Putten JP; van der Ley P
    Infect Immun; 2007 Dec; 75(12):5939-46. PubMed ID: 17908810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.
    Cross AS; Opal SM; Warren HS; Palardy JE; Glaser K; Parejo NA; Bhattacharjee AK
    J Infect Dis; 2001 Apr; 183(7):1079-86. PubMed ID: 11237833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.
    Zollinger WD; Babcock JG; Moran EE; Brandt BL; Matyas GR; Wassef NM; Alving CR
    Vaccine; 2012 Jan; 30(4):712-21. PubMed ID: 22138211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.
    Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS
    J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.
    Feiring B; Fuglesang J; Oster P; Naess LM; Helland OS; Tilman S; Rosenqvist E; Bergsaker MA; Nøkleby H; Aaberge IS
    Clin Vaccine Immunol; 2006 Jul; 13(7):790-6. PubMed ID: 16829617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.
    Sandbu S; Feiring B; Oster P; Helland OS; Bakke HS; Naess LM; Aase A; Aaberge IS; Kristoffersen AC; Rydland KM; Tilman S; Nøkleby H; Rosenqvist E
    Clin Vaccine Immunol; 2007 Sep; 14(9):1062-9. PubMed ID: 17634513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.